FANPEP <4881> announced on the 7th the non-clinical trial data of the allergy vaccine (antibody-inducing peptide 'FPP004X') that is under development, as well as the schedule for clinical trial start.

FPP004X can be expected to have a therapeutic effect by inducing antibody production against IgE (immunoglobulin E) that causes allergic reactions when bound to allergens such as pollen in the body. The company is developing pharmaceuticals with the aim of providing a new treatment option with high convenience for patients by administering it before pollen season to alleviate symptoms throughout the season.

In the non-clinical trials of FPP004X, it was confirmed that it induces anti-IgE antibodies and suppresses allergic reactions (decreases in eosinophil count and sniffing frequency) using an OVA-induced allergic rhinitis model in humanized IgE/FcεR1 transgenic mice. Currently, the target start time for phase 1 clinical trials is the first quarter of the fiscal year ending in December 2025, and non-clinical trials are ongoing.